Carnyx Moves Oral Sleep Drug CNYX-005 Into IND-Enabling Development
Image
INDIANAPOLIS – October 28, 2026 -- Carnyx Therapeutics has advanced its lead oral sleep candidate, CNYX-005, into Investigational New Drug (IND)-enabling development, bringing the preclinical asset closer to potential first-in-human studies.
Aged-rat data show 1.5 to 2 hours of added sleep
In recently reported preclinical findings, CNYX-005 increased total sleep time by roughly 1.5 to 2 hours versus controls in aged rats. The gain was driven primarily by increased non-rapid eye movement (NREM) sleep. Chief Medical Officer Chris Brearley said existing treatments are limited by safety, tolerability and long-term use concerns, which he cited as the case for additional options.